Denmark-based non-invasive human diagnostics company, RSP Systems has received grant to support the market launch of its non-invasive glucose monitor, GlucoBeam.

The €2.4m grant is a part of European Union's Horizon 2020 framework for research and innovation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

RSP Systems CEO Dr Anders Weber said: "This vital grant will help to overcome the biggest issue in glucose monitoring: compliance.

"For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam will be a real breath of fresh air."

"For patients to finally be able to measure their glucose levels using the non-invasive GlucoBeam will be a real breath of fresh air.

"With the completion of a commercial product aided by Horizon 2020, we can now identify the best path to the best partners to make GlucoBeam broadly available to patients in the European and later global markets."

See Also:

Based on RSP's proprietary and clinically validated technology, critical depth raman spectroscopy, GlucoBeam is used for glucose measurement in living tissue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is easy to use and is compliant with the recommended glucose monitoring schemes since the usage of the device causes no pain and inconvenience.

The device is wirelessly integrated with a smartphone/tablet app to store and analyse the glucose data which can be shared with physicians.

GlucoBeam is designed to support integration to cloud based Internet Blood Glucose Monitoring services. Sharing of the glucose data enables physicians to optimise their treatment while minimising chances of complications.